NEWDRINK: Effect of 6 Weeks Daily Consumption of a Cereal-based Juice Beverage on Gastrointestinal Health

Sponsor
University of Copenhagen (Other)
Overall Status
Completed
CT.gov ID
NCT03046667
Collaborator
Carlsberg Group (Other)
56
1
2
10.1
5.6

Study Details

Study Description

Brief Summary

The project is a randomized, 2-way, blinded parallel trial in which 56 healthy adults of both genders with frequent occurrence of stomach trouble.This intervention trial with 6 weeks of daily intake β-glucans will be carried out with a beverage containing β-glucans and a control beverage without β-glucans. The primary aim is to investigate whether β-glucans from barley has an effect on stomach and intestinal health, including stool volume and frequency. Microbiota, concentrations of short chain fatty acids (butyrate, propionate, acetate), calprotectin, and energy and fat content in feces. Furthermore, blood pressure and exhaled hydrogen and methane, before and after the intervention, subjective perception of gastrointestinal problems and digestion as well as the participants' attitudes towards functional foods are measured using Visual Analog Scale (VAS).

Further, specific metabolites of β-glucans in urine (exploratory endpoint) and certain toxic metabolites from the microbiota using metabolite profiling (metabolomics) are also analyzed

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Barley β-glucan
  • Dietary Supplement: Control
N/A

Detailed Description

β-glucans from barley slows gastric emptying rate and prolongs the transit time of food in the small intestine." The relatively undigested β-glucans have the ability to increase satiety and stimulate digestion, ensuring regular bowel movements and relieve sluggish bowel movements, including constipation and constipation. β-glucans are fermented down in the large intestine, resulting in production of short-chain fatty acids which inhibit the biosynthesis of cholesterol, hence blood cholesterol levels are lowered (not the goal here). Subsequently, β-glucans may also affect blood pressure. As a direct result of the effects in the intestine, there will be an improvement in the quality of life for people with stomach upsets and maybe a reduction in the risk of cardiovascular disease.

Study Design

Study Type:
Interventional
Actual Enrollment :
56 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
The beverages are provided to the investigator and volunteers with similar color, taste and bottles, only labelled A or B.
Primary Purpose:
Prevention
Official Title:
Effect of 6 Weeks Daily Consumption of a Cereal-based Juice Beverage on Gastrointestinal Health
Actual Study Start Date :
Feb 8, 2017
Actual Primary Completion Date :
Jul 20, 2017
Actual Study Completion Date :
Dec 11, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Test drink

Test drink: Barley β-glucan

Dietary Supplement: Barley β-glucan
The test beverages with Barley β-glucan is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks consumed for 5 weeks. In total was the test drinks consumed for 6 weeks.
Other Names:
  • barley beta-glucan beverages
  • Placebo Comparator: Control drink

    Control drink: barley beverage

    Dietary Supplement: Control
    The control beverages is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks
    Other Names:
  • barley drink
  • Outcome Measures

    Primary Outcome Measures

    1. Stool volume [0 and 6 weeks]

      Changes in total stool weight 2 x 3 days from 72 hours before study start and 72 hours before study termination after 6 weeks, determined by a mixed model analysis.

    Secondary Outcome Measures

    1. Hydrogen [0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330 and 360 min]

      Changes in exhaled hydrogen concentrations determined by a mixed model analysis and subsequently at each time point with 0 as a co-variate.

    2. Methane [0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330 and 360 min]

      Changes in exhaled methane concentrations determined by a mixed model analysis and subsequently at each time point with 0 as a co-variate.

    3. Hydrogen Area Under the Curve [-2, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330 and 360 min]

      Area Under the Curve (AUC) for exhaled hydrogen

    4. Methane Area Under the Curve [-2, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330 and 360 min]

      Area Under the Curve (AUC) for exhaled methane

    5. Fecal concentrations of SCFA [0 and 6 weeks]

      Changes in SCFA concentrations determined by a mixed model analysis

    6. Determination and variations in fecal microbiota [0 and 6 weeks]

      Changes in microbiota determined by a mixed model analysis

    7. Fecal concentrations of calprotectin [0 and 6 weeks]

      Changes in calprotectin concentrations determined by a mixed model analysis

    Other Outcome Measures

    1. Metabolic profile in 24h urine collections [0 and 6 weeks]

      Untargeted metabolic profile of urine samples measured in all samples collected 24 hours before the intervention with beta glucans as well as in samples collected 6 weeks later 24 hours before study termination. The totality of the profiles is used to explore for changes after baseline as detected by multivariate statistics (PLS-DA)

    2. Metabolic profile in 3d fecal collections [0 and 6 weeks]

      Untargeted metabolic profile of fecal samples measured in all samples collected 72-0 hours before the intervention with beta glucans as well as in samples collected 6 weeks later 72-0 hours before study termination. The totality of the profiles is used to explore for changes after baseline as detected by multivariate statistics (PLS-DA)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 55 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • BMI 20 - 27 kg/m2

    • Like test and control drink, pasta, meat sauce as these foods are part of the test meal.

    • Healthy subjects sometimes or often bothered by mild gastric problems such as bloating, loose stools or constipation

    • Willing to handle in 2 x 3-day total feces at the start and end of the study

    Exclusion Criteria:
    • Suffering from irritable bowel syndrome (IBS), bacterial overgrowth in the small intestine (SIBO) or inflammatory bowel disease (IBD).

    • Systemic infections, psychiatric or metabolic diseases, and any clinical condition

    • Chronic or frequent use of medication (including blood thinners, excluding contraceptives)

    • Frequent loose stools

    • Blood donations during or in the month leading up to the study period

    • Elite athletes (> 10 hours of hard exercise / week, self-reported)

    • High intake of alcohol (defined as a weekly intake of > 7 units for women and > 14 units for men),

    • Have or have had a drug addiction

    • Participation in other scientific studies during the study period

    • Lactating

    • Pregnancy or ongoing planning of pregnancy

    • Vegetarianism or veganism.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Nutrition, Exercise and Sports, University of Copenhagen Frederiksberg Denmark 1958

    Sponsors and Collaborators

    • University of Copenhagen
    • Carlsberg Group

    Investigators

    • Principal Investigator: Lars Ove Dragsted, PhD, University of Copenhagen

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Professor Lars Ove Dragsted, Professor, University of Copenhagen
    ClinicalTrials.gov Identifier:
    NCT03046667
    Other Study ID Numbers:
    • M230
    First Posted:
    Feb 8, 2017
    Last Update Posted:
    Dec 13, 2017
    Last Verified:
    Dec 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Professor Lars Ove Dragsted, Professor, University of Copenhagen
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 13, 2017